OGN - Organon & Co. Stock Price, Fair Value and News

$15.14+0.25 (+1.68%)

Delayed as of 22 Nov 2024, 11:01 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OGN Price Action

Last 7 days

-2.8%

Last 30 days

-14.2%

Last 90 days

-33.4%

Trailing 12 Months

32.4%

OGN RSI Chart

OGN Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

2.95

Price/Sales (Trailing)

0.6

EV/EBITDA

8.28

Price/Free Cashflow

5.13

OGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OGN Fundamentals

OGN Revenue

Revenue (TTM)

6.4B

Rev. Growth (Yr)

4.15%

Rev. Growth (Qtr)

-1.56%

OGN Earnings

Earnings (TTM)

1.3B

Earnings Growth (Yr)

518.97%

Earnings Growth (Qtr)

84.1%

OGN Profitability

EBT Margin

12.20%

Return on Equity

263.89%

Return on Assets

10.2%

Free Cashflow Yield

19.48%

OGN Investor Care

Dividend Yield

7.52%

Dividend/Share (TTM)

1.12

Shares Dilution (1Y)

0.76%

Diluted EPS (TTM)

5.04

OGN Alerts

Big jump in Earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.3B	6.3B	6.4B	0
2023	6.1B	6.2B	6.2B	6.3B
2022	6.4B	6.4B	6.3B	6.2B
2021	6.3B	6.3B	6.3B	6.3B
2020	7.5B	7.2B	6.8B	6.5B
2019	0	0	0	7.8B

Get all data in R, Python etc through our Historical Stock Data APIs

About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

CEO	Mr. Kevin Ali
WEBSITE	organon.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	10000

Organon & Co. Frequently Asked Questions

What is the ticker symbol for Organon & Co.? What does OGN stand for in stocks?

OGN is the stock ticker symbol of Organon & Co.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organon & Co. (OGN)?

As of Thu Nov 21 2024, market cap of Organon & Co. is 3.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OGN stock?

You can check OGN's fair value in chart for subscribers.

Is Organon & Co. a good stock to buy?

The fair value guage provides a quick view whether OGN is over valued or under valued. Whether Organon & Co. is cheap or expensive depends on the assumptions which impact Organon & Co.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGN.

What is Organon & Co.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, OGN's PE ratio (Price to Earnings) is 2.95 and Price to Sales (PS) ratio is 0.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGN PE ratio will change depending on the future growth rate expectations of investors.